| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite 5-HT1 Receptor 5-HT2 Receptor 5-HT4 Receptor 5-HT5 Receptor 5-HT6 Receptor 5-HT7 Receptor
5-Methoxytryptamine targets multiple serotonin (5-HT) receptor subtypes. It is a non-selective full agonist at 5-HT1, 5-HT2, 5-HT4, 5-HT6, and 5-HT7 receptors, while having no affinity for the 5-HT3 receptor. It shows binding affinity for the rat brain 5-HT1A receptor with a Ki of 11 nM. By activating these receptors, the compound modulates serotonergic signaling pathways involved in mood regulation, gastrointestinal motility, and neurotransmitter release. |
|---|---|
| ln Vitro |
In vitro, 5-Methoxytryptamine acts as a non-selective full agonist at multiple 5-HT receptor subtypes. Its activity is typically assessed by measuring its ability to stimulate cAMP accumulation or calcium mobilization in cells expressing various 5-HT receptors. The compound exhibits antioxidant properties in cell-based assays. It is used as a research reagent for serotonin receptor assays and to study the role of serotonergic signaling in various physiological and pathological processes.
|
| ln Vivo |
5-Methoxytryptamine dosages more than 1 mg/kg in rats result in significant hyperglycemia [1].
In vivo, 5-Methoxytryptamine is used in research to study serotonin receptor-mediated effects. As a metabolite of Melatonin, it may contribute to the physiological effects of melatonin through serotonin receptor activation. The compound's non-selective agonist profile makes it useful for studying the integrated effects of serotonin receptor activation. Its radioprotective properties have been investigated in pre-clinical models. However, comprehensive in vivo pharmacological studies are limited. |
| Enzyme Assay |
For non-cell-based receptor binding assays, 5-Methoxytryptamine can be evaluated using membrane preparations from tissues or cells expressing various 5-HT receptor subtypes. Radioligand binding displacement experiments are performed using suitable radiolabeled ligands such as [3H]-8-OH-DPAT for 5-HT1A, [3H]-ketanserin for 5-HT2A, or [3H]-GR113808 for 5-HT4. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-90 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled ligand. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing various 5-HT receptor subtypes are cultured in appropriate media. For functional assays, the appropriate signaling readout is measured depending on the receptor subtype (e.g., cAMP accumulation for Gs-coupled receptors, calcium mobilization for Gq-coupled receptors). Cells are treated with various concentrations of 5-Methoxytryptamine, and the signaling response is measured using fluorescent indicators or ELISA-based detection. EC50 values are calculated from dose-response curves. For antioxidant assays, cells are treated with oxidative stressors in the presence or absence of the compound, and oxidative stress markers are measured.
|
| Animal Protocol |
For in vivo animal studies, 5-Methoxytryptamine can be administered to rodents via intraperitoneal injection. In models of serotonin-mediated behaviors, its effects on locomotion, anxiety, and gastrointestinal motility are assessed. In radioprotection studies, the compound's ability to protect against radiation-induced damage is evaluated. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
5-Methoxytryptamine's known human metabolites include serotonin. 5-Methoxytryptamine has a molecular weight of 190.24 and a molecular formula of C11H14N2O. It is supplied as a crystalline solid with a purity of ≥98%. The compound is soluble in water and DMSO. It should be stored at -20°C for long-term stability. It is provided as a research-grade reagent for studies of serotonin receptor activity, antioxidant effects, and radioprotective actions. |
| Toxicity/Toxicokinetics |
The toxicity profile of 5-Methoxytryptamine has not been extensively reported. As a non-selective serotonin receptor agonist, potential adverse effects may include modulation of serotonergic signaling, which could affect mood, gastrointestinal function, and cardiovascular regulation. The compound is for research use only and is not intended for human consumption. Standard safety precautions should be observed when handling the compound.
|
| References |
|
| Additional Infomation |
5-Methoxytryptamine is a tryptamine compound and a methyl ether derivative of serotonin. It has multiple functions, including acting as a serotonergic agonist, a human metabolite, a mouse metabolite, a 5-hydroxytryptamine 2A receptor agonist, a 5-hydroxytryptamine 2C receptor agonist, a 5-hydroxytryptamine 2B receptor agonist, an antioxidant, a radiation protectant, a neuroprotective agent, and a cardioprotective agent. It belongs to the tryptamine class of compounds, is an aromatic ether, and is also a primary amino compound. Its function is related to serotonin. It is the conjugate base of 5-methoxytryptamine (1+). It has been reported that 5-methoxytryptamine is present in Mimosa somnians, Cinchona calisaya, and Caenorhabditis elegans, and relevant data exist. Serotonin derivatives are considered potential synergists for hypnotics and sedatives. See also: ... See more...
5-Methoxytryptamine (O-Methylserotonin, CAS 608-07-1) is a non-selective serotonin receptor agonist and a derivative of serotonin. It acts as a full agonist at multiple 5-HT receptor subtypes. It is a metabolite of Melatonin and exhibits antioxidant and radioprotective properties. It is used in biochemical and neuroscience applications to study serotonin receptor activity. It is available for research purposes only. |
| Molecular Formula |
C11H14N2O
|
|---|---|
| Molecular Weight |
190.25
|
| Exact Mass |
205.073
|
| CAS # |
608-07-1
|
| Related CAS # |
5-Methoxytryptamine hydrochloride;66-83-1
|
| PubChem CID |
1833
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
445.9±30.0 °C at 760 mmHg
|
| Melting Point |
121.5 °C
|
| Flash Point |
223.5±24.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
1.34
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
186
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC2=C(C=C1)NC=C2CCN
|
| InChi Key |
JTEJPPKMYBDEMY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3
|
| Chemical Name |
2-(5-methoxy-1H-indol-3-yl)ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 200 mg/mL (1051.25 mM)
Ethanol: 100 mg/mL (525.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (26.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (26.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2562 mL | 26.2812 mL | 52.5624 mL | |
| 5 mM | 1.0512 mL | 5.2562 mL | 10.5125 mL | |
| 10 mM | 0.5256 mL | 2.6281 mL | 5.2562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
